INMBInmune Bio, Inc.vs its industry peers
A metric-by-metric comparison of Inmune Bio, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INMBEsta | $65M#8 | — | 3.2x#7 | 1307.2x#7 | 257.1%#2 | -9.5%#5 | -94766.0%#7 | -225.9%#8 | -607.3%#2 | — | 19.5%#4 | — |
| BSEM | $90M#2 | — | 3.3x#8 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PTHS | $88M#3 | — | — | 5.2x#3 | — | -444.6%#14 | -193.1%#3 | — | — | — | -27.3%#8 | — |
| SCTX | $651M#1 | — | — | — | — | — | — | — | — | — | — | — |
| VXRT | $80M#4 | 2.0x#1 | 1.0x#3 | 0.3x#1 | 726.7%#1 | 124.4%#1 | 7.6%#1 | 0.0%#1 | 22.5%#1 | — | -24.0%#7 | — |
| CSBR | $76M#5 | — | 19.6x#10 | 1.3x#2 | 4.4%#3 | -125.0%#13 | -1.9%#2 | -0.0%#3 | — | — | -16.1%#5 | — |
| KLRS | $73M#6 | — | 1.3x#4 | 441.5x#5 | — | 37.2%#2 | -27970.9%#6 | -75.3%#7 | — | — | -30.8%#9 | — |
| ELOX | $72M#7 | 5.0x#2 | 1.6x#5 | — | -100.0%#5 | -90.7%#11 | — | -12.9%#4 | — | — | — | — |
| LONA | $65M#9 | — | 1.9x#6 | — | — | -9.3%#4 | — | -315.5%#10 | — | — | 79.6%#3 | — |
| EXOZ | $62M#10 | — | 17.0x#9 | 887.5x#6 | — | -56.3%#10 | -13867.0%#5 | -250.6%#9 | — | — | -44.1%#11 | — |
| INKT | $59M#11 | — | — | — | — | -15.9%#6 | — | — | — | — | -19.0%#6 | — |
| IMA | $58M#12 | — | 0.4x#1 | 72.6x#4 | -77.1%#4 | -24.0%#7 | -6056.4%#4 | -31.9%#5 | — | — | -39.7%#10 | — |
| BKHAU | $53M#13 | — | — | — | — | -30.6%#8 | — | — | — | — | 133.8%#1 | 96.2%#2 |
| TVGN | $50M#14 | — | — | — | — | -91.4%#12 | — | — | — | — | -81.7%#13 | — |
| BKHA | $49M#15 | — | — | — | — | -30.6%#8 | — | — | — | — | 126.3%#2 | 104.1%#1 |
| TIL | $49M#16 | — | 0.5x#2 | — | -100.0%#5 | 3.7%#3 | — | -66.5%#6 | — | — | -66.5%#12 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice